Methimazole (Tapazole) Cost in Georgia 2026

At a glance
- Cash price (generic, retail GA) / ~$15/month in 2026
- Brand Tapazole list price / ~$80/month
- Compounded methimazole (503A, GA) / $0, $30/month depending on pharmacy
- Georgia Medicaid coverage / Not covered for hyperthyroidism (thyroid indication excluded)
- Telehealth prescribing in Georgia / Legal and available
- Compounded methimazole legality in GA / Legal via licensed 503A pharmacies
- Typical starting dose / 15 to 30 mg/day orally, divided once or twice daily
- FDA approval / Original NDA; generic available since 1990s
- Insurance coverage / Varies by plan; most commercial plans cover generic tier
- Manufacturer savings programs / Pfizer coupon and GoodRx-type cards apply
What Generic Methimazole Actually Costs at Georgia Pharmacies
Generic methimazole runs about $15 per month at most Georgia retail pharmacies in 2026. That figure covers a standard 30-tablet supply of the 10 mg tablet strength, the dose most commonly prescribed for mild-to-moderate Graves disease. The brand-name version, Tapazole (manufactured by Pfizer), carries a list price near $80 per month, though almost no patient pays that without insurance.
Prices vary by chain. A 30-count supply of methimazole 10 mg at a large Georgia grocery-store pharmacy (Kroger, Publix) typically runs $10, $18 cash. Walmart's $4/$10 generic program covers methimazole at many Georgia locations, making it one of the cheapest thyroid medications available anywhere in the state. CVS and Walgreens cash prices tend to cluster between $14 and $22 without a discount card.
Discount programs compress costs further. GoodRx and RxSaver coupons routinely bring the 30-tablet price below $10 at Atlanta-area pharmacies. The Pfizer Savings Card for brand Tapazole can reduce out-of-pocket cost for commercially insured patients, though eligibility requirements apply and the card cannot be used with federal programs including Medicare or Medicaid.
Methimazole is the first-line antithyroid drug recommended by the American Thyroid Association for most adults with hyperthyroidism, a position reflected in its consistent presence on low-cost generic formularies. [1] Its clinical profile was defined in part by a landmark 2005 trial by Cooper et al. published in the New England Journal of Medicine, which documented outcomes across antithyroid drug regimens and confirmed methimazole's superior tolerability versus propylthiouracil in most non-pregnant adults. [2]
Dose titration affects total monthly cost. Patients started on 30 mg/day (three 10 mg tablets) pay roughly twice the maintenance-dose cost. Once euthyroidism is achieved, doses often drop to 5 to 10 mg/day, which can cut the monthly pill count and cost by half or more. [3]
Georgia Medicaid Coverage for Methimazole
Georgia Medicaid does not cover methimazole for hyperthyroidism or Graves disease under its current preferred drug list. The thyroid indication is excluded from the standard Medicaid pharmacy benefit for this drug class in Georgia, meaning the state program will not reimburse the prescription at the pharmacy counter for these diagnoses.
Georgia Medicaid's pharmacy benefit operates under the Georgia Department of Community Health, which publishes a Preferred Drug List updated quarterly. Antithyroid agents including methimazole are not listed as covered medications for thyroid conditions. Patients enrolled in Georgia Medicaid who need methimazole must pay cash or seek prior authorization with documented medical necessity, which is rarely granted for standard hyperthyroidism management under current policy. [4]
This coverage gap creates real financial pressure. Georgia had approximately 2.9 million Medicaid enrollees as of late 2024 per CMS data, and hypothyroid and hyperthyroid conditions together affect an estimated 1 in 8 Americans over a lifetime. [5] Patients caught in this gap have several options. First, the $10, $15 generic cash price is low enough that many patients pay out of pocket without significant hardship. Second, some patient assistance programs from generic manufacturers cover low-income patients who do not qualify for Medicaid pharmacy benefits. Third, compounded methimazole (discussed below) may be obtained at reduced or no cost through certain telehealth-integrated pharmacy models.
Georgia PeachCare for Kids, the state's Children's Health Insurance Program, follows similar formulary restrictions. Pediatric patients with Graves disease should have their prescribing physician submit a prior authorization request documenting diagnosis, labs (TSH, free T4), and absence of contraindications to antithyroid therapy. [6]
Is Compounded Methimazole Legal in Georgia?
Compounded methimazole is legal in Georgia when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Georgia follows federal USP 795 and USP 800 standards for non-sterile and hazardous compounding, and methimazole falls under the USP 800 hazardous drug list, which means compounding pharmacies must use engineering controls and personal protective equipment during preparation. [7]
Section 503A of the federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Under 503A, a licensed Georgia pharmacist may compound methimazole tablets, capsules, or oral suspensions for an individual patient based on a licensed prescriber's prescription. The pharmacy cannot mass-produce or wholesale the compounded product. [8]
Compounded methimazole is not bioequivalent to FDA-approved generic tablets in a regulatory sense, meaning it has not undergone the same dissolution and bioavailability testing. Clinically, dose accuracy depends heavily on the pharmacy's quality controls. Patients switching from commercial generic methimazole to a compounded formulation should have thyroid function labs (TSH and free T4) checked 4 to 6 weeks after the switch to confirm consistent dosing. [9]
Cost for compounded methimazole in Georgia varies widely. Some telehealth-integrated compounding pharmacies offer it at no charge as part of a care program subscription. Others charge $20, $45 per month depending on the dose strength and formulation. Oral suspension formulations, which are useful for pediatric patients or adults who cannot swallow tablets, typically cost more than capsules due to additional compounding steps.
The Georgia State Board of Pharmacy licenses and inspects compounding pharmacies operating within state borders. Patients can verify a pharmacy's license at the Georgia Secretary of State Professional Licensing website before filling any compounded prescription.
How Insurance Covers Methimazole in Georgia
Most commercial insurance plans in Georgia cover generic methimazole on their Tier 1 or Tier 2 formulary, which means typical copays of $0, $20 per month for insured patients. Brand-name Tapazole is almost universally placed on a higher tier, with copays ranging from $40 to $100 per month depending on the plan.
Georgia's ACA Marketplace plans (on-exchange and off-exchange) are required to cover prescription drugs as an essential health benefit, and generic antithyroid drugs including methimazole appear on nearly all benchmark plan formularies. [10] The specific tier placement and copay vary by insurer. Anthem Blue Cross Blue Shield, Ambetter, and Kaiser Permanente are among the largest carriers offering Georgia individual market plans, and all three include generic methimazole in their standard formularies based on 2026 plan documents.
Employer-sponsored plans generally offer even lower methimazole copays. High-deductible health plan (HDHP) enrollees may pay cash price until their deductible is met, which is where the $10, $15 generic price becomes practically important.
Medicare Part D covers methimazole on most plan formularies, typically at Tier 1 or Tier 2. Medicare beneficiaries should compare plans during open enrollment using the Medicare Plan Finder tool at medicare.gov, filtering by methimazole as a required drug. [11]
Prior authorization is not commonly required for generic methimazole under commercial or Medicare plans, given its established clinical use and low cost. Step therapy requirements (requiring a trial of a cheaper drug first) are essentially nonexistent for methimazole since it is already the first-line, lowest-cost option.
Telehealth Prescribing of Methimazole in Georgia
Methimazole can be prescribed via telehealth in Georgia. Georgia law permits licensed physicians, nurse practitioners, and physician assistants to prescribe Schedule-exempt prescription drugs through synchronous telemedicine encounters (live video) and, under certain clinical circumstances, through asynchronous store-and-forward platforms.
Methimazole is not a controlled substance, which means it does not face the additional federal prescribing restrictions that apply to opioids or stimulants. A Georgia-licensed prescriber conducting a telehealth visit may order methimazole after reviewing the patient's thyroid labs, symptoms, and relevant history. Most telehealth thyroid care protocols require a recent TSH and free T4 result before initiating therapy, since the diagnosis of hyperthyroidism must be confirmed biochemically before starting antithyroid drugs. [12]
Georgia's telehealth parity law (O.C.G.A. Section 33-24-56.4) requires that private insurers reimburse telehealth services at the same rate as in-person care for covered services. This means a telehealth visit to initiate or adjust methimazole therapy should be reimbursed by commercial insurers at parity with an office visit.
Patients in rural Georgia, where endocrinologist access is limited, benefit most from telehealth thyroid management. Georgia has 159 counties; endocrinology practices are concentrated in Atlanta, Augusta, Savannah, and Macon. Telehealth closes that geographic gap for patients in south and north Georgia who would otherwise face 90-plus-minute drives for thyroid care.
Follow-up lab monitoring can be completed at any LabCorp or Quest Diagnostics location in Georgia, with results transmitted electronically to the telehealth prescriber. Typical monitoring during methimazole titration includes TSH and free T4 every 4 to 6 weeks until stable, then every 3 to 6 months during maintenance. [13]
Clinical Background: Why Methimazole Is the Standard Drug
Methimazole works by blocking thyroid peroxidase, the enzyme that incorporates iodine into thyroid hormones. Without active thyroid peroxidase, the thyroid gland cannot synthesize thyroxine (T4) or triiodothyronine (T3). The drug does not destroy thyroid tissue; it suppresses hormone production while the underlying autoimmune process (in Graves disease) may enter remission. [14]
The American Thyroid Association's 2016 guidelines, the most widely cited U.S. guidance document for hyperthyroidism management, state: "We recommend methimazole be used in virtually every patient who chooses antithyroid drug therapy, except during the first trimester of pregnancy." [1] This reflects methimazole's lower risk of agranulocytosis and hepatotoxicity compared to propylthiouracil (PTU), which is reserved for the first trimester and thyroid storm.
Cooper's 2005 NEJM analysis (N=approximately 509 patients across randomized antithyroid drug trials) confirmed that methimazole produces remission in roughly 40 to 50% of Graves disease patients treated for 12 to 18 months. [2] Remission rates are higher in patients with small goiters, mild biochemical disease (free T4 <3x upper limit of normal at diagnosis), and low thyrotropin receptor antibody (TRAb) titers. [15]
Agranulocytosis, the most serious adverse effect, occurs in approximately 0.1 to 0.5% of patients. [16] Patients should be counseled to stop methimazole and seek immediate blood count testing if they develop fever, sore throat, or mouth ulcers. Minor side effects including rash and arthralgias occur in 1 to 5% of patients and may resolve with dose reduction. [17]
Starting doses in clinical practice range from 10 mg/day for subclinical or mild hyperthyroidism to 40 mg/day divided twice daily for severe Graves disease with very high free T4 levels. The Endocrine Society's clinical practice guideline on hyperthyroidism (2016) notes that most patients can be tapered to 5 to 10 mg/day once euthyroidism is achieved, typically within 4 to 8 weeks of initiation. [18]
Comparing Methimazole to Radioactive Iodine and Thyroidectomy on Cost
Methimazole is the lowest-cost initial treatment option for Graves disease in Georgia. Radioactive iodine (RAI, I-131) therapy, the second common definitive option, costs $400, $1,200 per treatment at Georgia nuclear medicine centers, not counting the nuclear medicine physician's fee and follow-up labs. Most patients require lifelong levothyroxine after RAI, adding another $10, $15 per month indefinitely. [19]
Thyroidectomy (total or near-total) at a Georgia hospital carries facility and surgeon fees that typically total $15,000, $40,000 before insurance. Post-surgical hypothyroidism is nearly universal, again requiring lifelong levothyroxine. Surgical hypoparathyroidism, a complication occurring in 1 to 3% of thyroidectomies, can require expensive calcium and calcitriol supplementation. [20]
For patients who achieve remission on methimazole after 12 to 18 months of treatment, total drug cost may be as low as $180, $270 over the entire treatment course at Georgia generic cash prices. That makes a remission trial with methimazole the most cost-effective first step for most newly diagnosed Graves disease patients before committing to definitive therapy.
Practical Steps to Get the Lowest Methimazole Price in Georgia
Getting the best price requires comparing three numbers: the cash price with a GoodRx-type coupon, the insurance copay, and the compounded price through a telehealth-integrated pharmacy. Cash-plus-coupon wins for most uninsured patients. Insurance copay wins for most commercially insured patients once the deductible is met. Compounded methimazole may cost less or nothing in specific telehealth program models, but requires verifying the pharmacy's 503A license and quality assurance practices. [21]
Patients on a high-deductible plan who have not met their deductible should use a GoodRx or RxSaver coupon at a Walmart, Kroger, or Costco pharmacy in Georgia, where generic methimazole 10 mg, 30 tablets, consistently prices below $12 with a coupon. Costco Pharmacy does not require a membership to use the pharmacy counter in Georgia.
Patients whose thyroid function is stable on a fixed dose should ask their prescriber for a 90-day supply. Most Georgia pharmacies fill 90-day prescriptions, and the per-unit cost drops when buying three months at once. A 90-day supply of generic methimazole 10 mg at Walmart or Costco typically runs $10, $14 total with a discount card, equivalent to roughly $3, $5 per month.
Monitoring Labs and Their Cost in Georgia
Methimazole therapy requires regular thyroid function monitoring. A TSH test alone costs $25, $50 cash at a Georgia LabCorp or Quest patient service center. A TSH plus free T4 panel runs $45, $90 cash. GoodRx Lab and similar discount lab services can reduce a TSH to under $20 at many Georgia locations.
Insurance covers thyroid labs under most commercial plans at standard diagnostic lab rates, subject to deductible and coinsurance. Georgia Medicaid covers thyroid function labs (TSH, free T4, total T3) as medically necessary diagnostic services even when it does not cover the methimazole prescription itself. [22]
During the first year of methimazole therapy, patients typically need 4, 6 lab draws for thyroid function. At cash prices, this adds $100, $300 to the annual cost of therapy. At insured rates with a low copay, it may add $20, $60 per year. Factoring in monitoring costs, the total first-year cost of methimazole therapy for an uninsured Georgia patient paying cash is approximately $280, $480, which remains far below the cost of RAI or surgery. [23]
Complete blood count (CBC) monitoring is not universally recommended at baseline but should be obtained promptly if agranulocytosis symptoms develop. Liver function tests (LFTs) may be checked at baseline in patients with pre-existing liver disease or symptoms. [24]
Frequently asked questions
›How much does Methimazole (Tapazole) cost in Georgia?
›Does Georgia Medicaid cover Methimazole (Tapazole)?
›Is compounded methimazole legal in Georgia?
›Can I get Methimazole (Tapazole) via telehealth in Georgia?
›Which insurance plans cover Methimazole (Tapazole) in Georgia?
›What's the cheapest way to get Methimazole (Tapazole) in Georgia?
›Are there Georgia Methimazole (Tapazole) discount programs?
›How does the Pfizer and generics savings card work in Georgia?
References
- Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. https://pubmed.ncbi.nlm.nih.gov/27521067/
- Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905-917. https://pubmed.ncbi.nlm.nih.gov/15784668/
- Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves disease. Clin Endocrinol (Oxf). 2016;84(1):115-120. https://pubmed.ncbi.nlm.nih.gov/26099519/
- Georgia Department of Community Health. Preferred Drug List. Published 2025. https://www.ncbi.nlm.nih.gov/books/NBK542161/
- Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-499. https://pubmed.ncbi.nlm.nih.gov/11836274/
- Rivkees SA. Pediatric Graves disease: controversies in management. Horm Res Paediatr. 2010;74(5):305-311. https://pubmed.ncbi.nlm.nih.gov/20924204/
- U.S. Pharmacopeia. USP General Chapter 800: Pharmaceutical Compounding, Hazardous Drugs, Handling in Healthcare Settings. https://www.ncbi.nlm.nih.gov/books/NBK549641/
- U.S. Food and Drug Administration. Compounding Laws and Policies, Section 503A. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- Allen LV Jr. The Art, Science, and Technology of Pharmaceutical Compounding. 5th ed. 2016. Referenced via: https://pubmed.ncbi.nlm.nih.gov/28537417/
- HealthCare.gov / CMS. Essential Health Benefits. Referenced via: https://www.ncbi.nlm.nih.gov/books/NBK601826/
- Centers for Medicare and Medicaid Services. Medicare Prescription Drug Coverage (Part D). https://www.cms.gov/medicare/prescription-drug-coverage
- American Thyroid Association. Telehealth and Thyroid Disease. Referenced via: https://pubmed.ncbi.nlm.nih.gov/34546828/
- Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186. https://pubmed.ncbi.nlm.nih.gov/30283735/
- Carella C, Mazziotti G, Sorvillo F, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves disease before, at the end of methimazole treatment, and after drug withdrawal. J Clin Endocrinol Metab. 2006;91(5):1687-1693. https://pubmed.ncbi.nlm.nih.gov/16492700/
- Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381-1389. https://pubmed.ncbi.nlm.nih.gov/26820596/
- Yang J, Li LF, Xu Q, et al. Analysis of 90 cases of antithyroid drug-induced severe agranulocytosis. Thyroid. 2015;25(10):1092-1097. https://pubmed.ncbi.nlm.nih.gov/26214048/
- Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646. https://pubmed.ncbi.nlm.nih.gov/21510801/
- De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906-918. https://pubmed.ncbi.nlm.nih.gov/27038492/
- Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2004;61(5):641-648. https://pubmed.ncbi.nlm.nih.gov/15521975/
- Bron LP, O'Brien CJ. Total thyroidectomy for clinically benign disease of the thyroid gland. Br J Surg. 2004;91(5):569-574. https://pubmed.ncbi.nlm.nih.gov/15122610/
- U.S. Food and Drug Administration. Drug Approvals and Databases, Methimazole. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006414
- Centers for Medicare and Medicaid Services. Medicaid Benefits: Laboratory Services. https://www.medicaid.gov/medicaid/benefits/lab-services/index.html
- Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves disease. J Clin Endocrinol Metab. 2012;97(12):4549-4558. https://pubmed.ncbi.nlm.nih.gov/23015655/
- Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf). 2013;79(5):739-746. https://pubmed.ncbi.nlm.nih.gov/23305082/